Introduction – Hexarelin (5 mg) Overview and Business Context

Laboratory vial of Hexarelin peptide (5 mg) on a research bench
Hexarelin (5 mg) research‑grade vial, a dual‑action peptide for GH release and cardiac protection.

Hexarelin (sequence HD‑TK‑GL‑HR) is a synthetic growth‑hormone‑releasing peptide (GHRP) supplied in a 5 mg, research‑grade vial. Originally synthesized to map the somatotropic axis, it quickly attracted attention after animal studies showed a potent cardio‑protective signature—attenuating myocardial fibrosis, limiting ischemic necrosis, and dampening pro‑inflammatory cytokine bursts. The molecule’s short‑chain structure (six amino acids) enables high‑purity manufacturing and reliable quantitation, making it frequently researched for both endocrine‑signaling assays and heart‑muscle injury models. Because the same peptide can be used to stimulate GH secretion and to explore myocardial resilience, Hexarelin occupies a unique niche that many labs label as a “dual‑purpose research tool.”

Research Use Only – NOT FOR HUMAN CONSUMPTION. This mandatory disclaimer satisfies FDA↗ RUO classification, reinforces that the product is intended solely for in‑vitro, ex‑vivo, or animal‑model experiments, and obliges purchasers to follow strict labeling, storage, and disposal protocols. Any deviation toward clinical or off‑label use would breach federal regulations and expose both supplier and buyer to enforcement actions. Research into Hexarelin research peptide continues to expand.

Article Roadmap

  • Scientific overview: peptide chemistry, GH‑release mechanism, and the pre‑clinical evidence research examining cardio‑protection.
  • Regulatory framework: FDA RUO definitions, labeling requirements, and permissible experimental contexts.
  • Business model insight: YourPeptideBrand’s white‑label, on‑demand solution that lets clinics launch a branded Hexarelin line without inventory risk, custom packaging, or minimum order constraints.

For researchers typing “cardio‑protective peptide for research labs” into search engines, Hexarelin stands out as a high‑purity, well‑characterized candidate that can be ordered in single‑vial quantities, eliminating the need for anabolic pathway research pathway research pathway research research storage. YPB’s turnkey service adds value by handling label design, compliance documentation, and direct‑to‑customer dropshipping, allowing clinic owners to devote resources to protocol development, data analysis, and manuscript preparation rather than supply‑chain logistics. The model also offers a revenue stream: clinics can re‑brand the vial under their own logo, sell it to affiliated practitioners, or use it as a premium research offering within a broader peptide portfolio.

Hexarelin Chemistry & Mechanism of Action

Amino‑acid sequence and peptide class

Hexarelin is a short, synthetic growth‑hormone‑releasing peptide (GHRP) with the linear sequence His‑Asp‑Thr‑Lys‑Gly‑Leu‑His‑Arg (HDTKGLHR). This eight‑residue chain places it in the same family as other GHRPs that mimic the endogenous ghrelin motif, yet its unique C‑terminal arginine research has examined effects on receptor affinity and stability.

Chemical identity

The molecular formula of Hexarelin is C56H84N16O13, giving an exact monoisotopic mass of ≈ 1024.2 Da. Commercially supplied batches are routinely analyzed by analytical‑grade HPLC and mass spectrometry, with a purity specification of ≥ 95 % to ensure reproducible biological activity.

Synthesis via solid‑phase peptide synthesis (SPPS)

Research‑grade Hexarelin is typically produced using Fmoc‑based SPPS on a Rink amide resin. Each amino‑acid is coupled with a protected side chain, activated by HBTU/HOBt or similar reagents, then de‑protected stepwise to elongate the chain. After chain assembly, the peptide is cleaved from the resin with a TFA‑based cocktail, precipitated, and purified by reverse‑phase HPLC. The final lyophilized powder is sealed under nitrogen, guaranteeing stability for up‑to‑two‑year storage at –20 °C.

Receptor interaction: GHS‑R1a binding

Hexarelin binds with high affinity to the growth‑hormone secretagogue receptor type 1a (GHS‑R1a), the same GPCR that mediates ghrelin signaling. Ligand engagement triggers Gq‑protein activation, leading to phospholipase C‑β stimulation, intracellular Ca²⁺ release, and a modest rise in cAMP via adenylate cyclase cross‑talk.

Downstream signaling pathways

Beyond pituitary GH release, GHS‑R1a activation funnels into the MAPK cascade (ERK1/2) and the PI3K/Akt axis. In cardiomyocytes, these pathways converge to promote cell survival, inhibit fibroblast‑driven collagen deposition, and improve myocardial perfusion during ischemic stress. The net effect is a dual pharmacology: potent GH secretion coupled with direct cardioprotective signaling. Research into Hexarelin research peptide continues to expand.

Molecular diagram of Hexarelin highlighting each residue and its interaction site on the GHS‑R1a receptor
Figure 1: Hexarelin residue labeling and binding orientation within the GHS‑R1a pocket.

Dual Research Findings – GH‑Secretagogue and Cardio‑Protection

GH‑Secretagogue Activity in Rodent Models

In a controlled study of Sprague‑Dawley rats, a single intraperitoneal injection of Hexarelin at 5 mg kg⁻¹ produced a rapid surge in circulating GH-related research (GH). Compared with saline‑treated controls, plasma GH rose by approximately 280 % within the first 30 minutes, reaching its peak at 30 minutes post‑dose and gradually returning toward baseline by 90 minutes. The magnitude of this response was statistically significant (p < 0.01) and comparable to the effect of the established GH‑releasing peptide GHRP‑6.[PubMed 10852784] Research Use Only – findings are limited to pre‑clinical animal models and should not be extrapolated to human research application.

Cardio‑Protective Effects in Pre‑Clinical Cardiac Injury Models

A separate investigation examined Hexarelin’s impact on myocardial injury using two well‑established rat models: acute ischemia‑reperfusion (I/R) and chronic pressure overload induced by transverse aortic constriction (TAC). In the I/R protocol, rats receiving 5 mg kg⁻¹ Hexarelin 15 minutes before reperfusion exhibited a 31 % reduction in infarct size relative to untreated controls (p < 0.05). Histological analysis showed a 42 % decrease in collagen deposition**, indicating attenuated fibrosis.[PubMed 17923644] Research Use Only – data reflect short‑term dosing in rodents, not chronic human use.

Experimental Models and Quantitative Outcomes

  • Ischemia‑Reperfusion (I/R) Model: 30‑minute coronary artery occlusion followed by 2‑hour reperfusion; Hexarelin‑treated group showed a 31 % smaller infarct area and a 42 % reduction in interstitial fibrosis compared with vehicle.
  • Chronic Pressure Overload (TAC) Model: 8‑week study; Hexarelin administration (5 mg kg⁻¹ IP, three times weekly) limited left‑ventricular wall thickness increase by 18 % and preserved ejection fraction (EF ≈ 62 % vs. 48 % in controls).
  • Signal‑Transduction Findings: Western‑blot analysis revealed a 2.3‑fold increase in phosphorylated Akt and a 1.9‑fold rise in phosphorylated ERK1/2 in myocardial tissue 1 hour after Hexarelin dosing, research examining activation of pro‑survival pathways.[PubMed 17923644]

Study Limitations and RUO Disclaimer

While these pre‑clinical results are encouraging, several constraints must be acknowledged:

  1. Species Differences: Rodent endocrine and cardiovascular physiology differ markedly from humans, potentially altering dose‑response relationships.
  2. Pharmacokinetic Gaps: No human pharmacokinetic (PK) or pharmacodynamic (PD) data exist for Hexarelin; absorption, distribution, metabolism, and excretion remain undefined beyond the acute rodent window.
  3. Short‑Term Dosing Regimens: Both studies employed single or limited‑duration dosing schedules; chronic exposure effects, tolerance, or safety profiles have not been characterized.
  4. Endpoint Specificity: Outcomes focus on surrogate markers (GH surge, infarct size, fibrosis) rather than functional clinical endpoints such as exercise capacity or long‑term survival.

Research Use Only – all data presented are derived from peer‑reviewed animal investigations and are not intended for diagnostic, research-grade, or commercial application in humans.

Regulatory Landscape for RUO Peptides

FDA Guidance Overview

The U.S. Food and Drug Administration classifies a peptide sold under a “Research Use Only” (RUO) label as a non‑clinical product. The agency’s RUO guidance makes clear that such items may be distributed only to qualified researchers for laboratory investigations. Any implication that the product is intended for research-grade or diagnostic use in humans is a direct violation of federal law. Research into Hexarelin research peptide continues to expand.

Mandatory Label Elements

To stay compliant, every Hexarelin container must display a precise set of fields. The label should be legible, durable, and placed where it cannot be removed or obscured. Required items include:

  • Product name – e.g., “Hexarelin (5 mg)”.
  • Net quantity – total amount of peptide in the vial or vial pack.
  • Batch/lot number – for traceability in case of a recall.
  • Expiration date – based on stability data supplied by the manufacturer.
  • Storage conditions – temperature range, protection from light, etc.
  • RESEARCH USE ONLY – NOT FOR HUMAN CONSUMPTION – this statement must appear in bold, uppercase lettering, and occupy a prominent position on the front of the label.
Example of a compliant RUO label for Hexarelin showing required fields and the bold disclaimer
Example of a compliant RUO label for Hexarelin.

Marketing and Distribution Limits

RUO status imposes strict prohibitions on how the peptide can be promoted and where it can be sold. Claims that Hexarelin stimulates GH-related research or protects the myocardium are permissible only in peer‑reviewed scientific literature, not in marketing copy. Direct‑to‑research subject advertising, inclusion in pharmacy inventories, or listing on e‑commerce platforms that target researchers are all disallowed. Distribution must be limited to:

  • Qualified research institutions.
  • Licensed investigators who have signed a receipt acknowledging RUO status.
  • Wholesale channels that do not market the product for clinical use.

Risks of Non‑Compliance

Failure to adhere to FDA RUO rules can trigger swift enforcement actions. The agency may issue warning letters demanding immediate corrective measures, impose civil monetary penalties, or seize inventory deemed to be misbranded. In severe cases, criminal prosecution is possible if a company knowingly markets a peptide as a research-grade agent. Maintaining accurate labeling, clear internal SOPs, and robust documentation of every transaction is therefore essential for protecting both the business and its reputation. Research into Hexarelin research peptide continues to expand.

Business Opportunity for Clinics & Entrepreneurs

YourPeptideBrand (YPB) offers a fully turnkey, white‑label solution that lets health‑focused businesses bring Hexarelin 5 mg vials to market without the typical barriers of inventory, labeling, or regulatory paperwork. With on‑demand label printing, zero minimum‑order‑quantity (MOQ) dropshipping, and a dedicated compliance team, clinics can launch a branded peptide line in days rather than months.

Key Service Features

  • On‑demand labeling: Custom branding printed at the moment of order, eliminating the need for large pre‑printed batches.
  • No‑MOQ dropshipping: Each vial is shipped directly from YPB’s GMP‑certified facility to the end‑user, research examining effects on storage costs and risk.
  • Compliance support: Guidance on Research Use Only (RUO) labeling, FDA‑compliant marketing language, and documentation for audit trails.

YPB’s compliance team reviews every label to ensure it meets RUO requirements, includes the mandatory disclaimer, and aligns with FDA guidance on peptide marketing. This safeguard studies have investigated effects on audit risk and protects your brand’s reputation.

Revenue Streams Researchers may Activate

  • Internal research anabolic pathway research pathway research pathway research research purchase: Secure a consistent supply of Hexarelin for in‑house clinical studies or protocol development.
  • Private‑label resale: Offer the peptide under your clinic’s brand to research subjects seeking GH‑secretagogue support, leveraging YPB

    Practical Considerations – Ordering, Storage, and Safety

    Laboratory technician handling lyophilized peptide vials
    Proper handling of lyophilized Hexarelin ensures potency and safety.

    Lyophilized Hexarelin remains chemically stable for at least 12 months when stored at ‑20 °C in a dedicated freezer. The vials must be kept in a light‑restricted container—amber‑colored or wrapped in foil—to prevent photodegradation. Once reconstituted, the solution should be kept on ice and used within 48 hours; any remaining material must be discarded according to the laboratory’s hazardous waste protocol.

    Laboratory Safety Practices

    All personnel handling Hexarelin should wear appropriate personal protective equipment (PPE): nitrile gloves, safety goggles, and a lab coat. The material safety data sheet (MSDS) is available on the YPB portal and outlines acute toxicity, inhalation, and skin‑contact risks. In the event of a spill, isolate the area, absorb the peptide with a disposable absorbent, and decontaminate the surface with a 10 % sodium hypochlorite solution before disposal in a biohazard container.

    Shipping Options from YPB

    YPB offers three temperature‑controlled shipping tiers:

    • Standard Cryo‑Pack: Dry ice insulated box with a 48‑hour delivery window; real‑time tracking is provided.
    • Express Cryo‑Pack: Same‑day courier service for urgent orders, maintaining ‑20 °C throughout transit.
    • Customs‑Ready Documentation: All shipments include a RUO (Research Use Only) declaration, harmonized system code, and a commercial invoice that satisfies international customs requirements.

    Compliance Checklist for Clinic Purchasers

    Before accepting a Hexarelin shipment, verify the following items to stay within FDA RUO guidelines:

    • RUO label is clearly printed on each vial and matches the purchase order.
    • Batch record includes lot number, expiration date, and manufacturing date.
    • Inspect the outer packaging for damage, condensation, or broken seals.
    • Document the receipt temperature; confirm it is ≤ ‑15 °C.
    • Log storage conditions in the laboratory’s inventory system and schedule a quarterly stability review.

    Adhering to these practical steps guarantees that Hexarelin retains its cardio‑protective and GH‑secretagogue potency while keeping your clinic compliant and safe.

    Ethical Marketing & Compliance

    When research investigating Hexarelin or any other research‑use‑only (RUO) peptide, the language you choose determines whether you stay within FDA boundaries or cross into prohibited research-grade claims. Below are the key guidelines YourPeptideBrand (YPB) recommends for every website, brochure, or social‑media post.

    Allowed phrasing

    Stick to neutral, study‑focused language. For example:

    • “Research applications in GH‑release studies.”
    • “Used as a tool to investigate myocardial fibrosis in pre‑clinical models.”
    • “Suitable for in‑vitro assays exploring peptide‑receptor interactions.”

    Avoid any wording that implies research application, prevention, or research focus of a disease, such as “studies have investigated effects on heart failure risk” or “has been studied for effects on growth‑hormone deficiency.”

    Sample compliant copy

    Website blurb: “Hexarelin (5 mg) is supplied as a Research Use Only peptide. It is frequently researched for scientists conducting GH‑release assays or cardiac‑fibrosis investigations in laboratory settings.”

    Social‑media post (Twitter/LinkedIn):

    “Exploring peptide‑mediated GH release? Our RUO‑grade Hexarelin has been examined in studies regarding rigorous cardiovascular research without making research-grade claims. #PeptideScience #RUO #ResearchOnly”

    FDA enforcement policy snapshot

    The FDA’s “Regulation of Research Use Only (RUO) Products” guidance makes clear that any promotional material suggesting a clinical benefit is a misbranding violation. Read the full guidance here. Enforcement actions have included warning letters, product seizures, and civil penalties for companies that blur the line between research tools and marketed drugs.

    Tips for internal review before publishing

    • Run every draft through a compliance checklist that flags disease‑specific terms.
    • Require sign‑off from a qualified regulatory affairs specialist or legal counsel.
    • Maintain a version‑controlled repository of approved copy to prevent accidental reuse of non‑compliant language.
    • Schedule quarterly research protocols for marketing staff on updated FDA RU‑O interpretations.

    Conclusion and Call to Action

    Extensive pre‑clinical data demonstrate that hexarelin acts as a potent GH‑secretagogue while simultaneously protecting the myocardium from fibrosis and ischemic injury. These dual mechanisms have been replicated across multiple animal models, confirming its relevance for both endocrine and cardiovascular research. Importantly, hexarelin remains classified as Research Use Only (RUO), ensuring that its distribution complies with current FDA guidance and does not constitute a research-grade claim.

    YourPeptideBrand’s compliant white‑label pathway turns this scientific opportunity into a strategic business advantage. We provide on‑demand label printing, custom packaging, and direct dropshipping—all without minimum order quantities—so clinics can launch a fully FDA‑compliant peptide line under their own brand while avoiding inventory risk.

    • Regulatory‑first labeling and documentation
    • Scalable, on‑demand packaging solutions
    • Zero‑MOQ dropshipping for rapid market entry

    Ready to explore how hexarelin can expand your service portfolio? Contact YourPeptideBrand today for a personalized consultation and a complimentary sample kit. Our experts will guide you through the compliance process and help you bring a high‑quality RUO peptide to your research subjects or researchers with confidence.

    YourPeptideBrand – empowering clinics to innovate responsibly.

    References

    The following peer‑reviewed sources and regulatory guidance informed the discussion:

    Explore Our Complete Research Peptide Catalog

    Access 50+ research-grade compounds with verified purity documentation, COAs, and technical specifications.

    Third-Party Tested99%+ PurityFast Shipping
    Download CatalogBook a Call

Related Posts